W
Weiping Deng
Researcher at Novartis
Publications - 10
Citations - 1044
Weiping Deng is an academic researcher from Novartis. The author has contributed to research in topics: Nilotinib & Myeloid leukemia. The author has an hindex of 7, co-authored 10 publications receiving 857 citations.
Papers
More filters
Journal ArticleDOI
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Andreas Hochhaus,Giuseppe Saglio,Timothy P. Hughes,Richard A. Larson,Dong-Kee Kim,Surapol Issaragrisil,P. le Coutre,Gabriel Etienne,Pedro Enrique Dorlhiac-Llacer,Richard E. Clark,Ian W. Flinn,Hirohisa Nakamae,Breanne Donohue,Weiping Deng,Darshan Dalal,Hans D. Menssen,Hagop M. Kantarjian +16 more
TL;DR: Long-term results support the positive benefit-risk profile of frontline nilotinib 300 mg twice daily in patients with CML-CP, and few deaths in any arm were associated with CVEs, infections or pulmonary diseases.
Journal ArticleDOI
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
Andreas Hochhaus,Tamás Masszi,Francis J. Giles,Jerry Radich,David M. Ross,M.T. Gómez Casares,Andrzej Hellmann,Jesper Stentoft,Eibhlin Conneally,Valentín García-Gutiérrez,Norbert Gattermann,Wieslaw Wiktor-Jedrzejczak,P. le Coutre,Bruno Martino,Susanne Saussele,Hans D. Menssen,Weiping Deng,Nancy Krunic,Véronique Bédoucha,Giuseppe Saglio +19 more
TL;DR: The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment.
Journal ArticleDOI
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
David M. Ross,Tamás Masszi,María Teresa Gómez Casares,Andrzej Hellmann,Jesper Stentoft,Eibhlin Conneally,Valentín García-Gutiérrez,Norbert Gattermann,Philipp le Coutre,Bruno Martino,Susanne Saussele,Francis J. Giles,Jerald P. Radich,Giuseppe Saglio,Weiping Deng,Nancy Krunic,Véronique Bédoucha,Prashanth Gopalakrishna,Andreas Hochhaus +18 more
TL;DR: These results demonstrate the feasibility and durability of TFR following frontline nilotinib and emphasize the importance of sustained deep molecular response (DMR) for TFR.
Journal ArticleDOI
Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd
Richard A. Larson,Dong-Wook Kim,Surapol Issaragrilsil,Philipp le Coutre,Pedro Enrique Dorlhiac Llacer,Gabriel Etienne,Richard E. Clark,Ian W. Flinn,Hirohisa Nakamae,Andreas Hochhaus,Giuseppe Saglio,Hagop M. Kantarjian,Breanne Donohue,Weiping Deng,Hans D. Menssen,Timothy P. Hughes +15 more
TL;DR: NIL resulted in better MR vs IM across all Sokal risk groups, including higher rates of EMR and MR4.5 by 5 y, and is unlikely to change with longer f/u because, among pts without MMR by 5Y, few remained on core treatment at data cutoff.
Journal ArticleDOI
ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).
Richard A. Larson,Dong-Wook Kim,Saengsuree Jootar,Ricardo Pasquini,Richard E. Clark,Clarisse Lobo,Stuart L. Goldberg,Hirohiko Shibayama,Andreas Hochhaus,Giuseppe Saglio,Hagop M. Kantarjian,Charisse Kemp,Weiping Deng,Hans D. Menssen,Timothy P. Hughes +14 more
TL;DR: Data is presented based on a minimum follow-up of 5 calendar y of newly diagnosed CML-CP and NIL has shown superior efficacy vs IM in ENESTnd.